Cilag Acquires Exclusive Worldwide Rights of Argenx's Cusatuzumab (ARGX-110) for $1.6B
Shots:
- Cilag (subsidiary of Janssen) to get worldwide commercialization rights for Cusatuzumab- with an option for Argenx to take part in the US activities. Argenx to receive $300M upfront- $200M equity investment and up to $1.3M as milestone plus tiered royalties(ex- US) on sales
- The companies have agreed to share profit equally in the US and plans to evaluate cusatuzumab in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
- Cusatuzumab is an anti-CD70 Ab- currently evaluated with Vidaza (Azacitidine) in P-I/II & P-II trial for AML & high-risk MDS and r/r cutaneous T-cell lymphoma (CTCL) respectively
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
